Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kapil N Bhalla

Showing results (1-10 of 103) with videos related to

Pageof 11
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2005
Epigenetic and chromatin modifiers as targeted therapy of hematologic malignanciesKapil N Bhalla
Oncogene|December 10, 2003
Microtubule-targeted anticancer agents and apoptosisKapil N Bhalla
Blood|May 7, 2016
NEDD8 and HDACs: promising cotargets in AMLKapil N Bhalla, Warren Fiskus
Cancer Biology & Therapy|August 17, 2005
Importance of rational pre-clinical development: gemcitabine comes of ageRamona F Swaby, Kapil N Bhalla
Blood|September 26, 2009
Missteps in "tango" for epigenome targetingKeith D Robertson, Kapil N Bhalla
Cancer Journal (Sudbury, Mass.)|September 20, 2017
Targeting Histone Acetylation: Readers and Writers in Leukemia and CancerChristopher B Benton, Warren Fiskus, Kapil N Bhalla
Oncotarget|December 8, 2017
Targeting cistrome and dysregulated transcriptome of post-MPN sAMLSrdan Verstovsek, Warren Fiskus, Taghi Manshouri, et al.
Hematology/Oncology Clinics of North America|September 27, 2012
Role of additional novel therapies in myeloproliferative neoplasmsWarren Fiskus, Siddhartha Ganguly, Suman Kambhampati, et al.
Molecular Pharmacology|January 27, 2006
Potent inhibition of platelet-derived growth factor-induced responses in vascular smooth muscle cells by BMS-354825 (dasatinib)Zhengming Chen, Francis Y Lee, Kapil N Bhalla, et al.
Expert Opinion on Investigational Drugs|August 13, 2009
Investigational drugs targeting FLT3 for leukemiaCelalettin Ustun, David L DeRemer, Anand P Jillella, et al.
Pageof 11

Showing results (1-10 of 103) with videos related to

Sort By:
Pageof 11
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2005
Epigenetic and chromatin modifiers as targeted therapy of hematologic malignanciesKapil N Bhalla
Oncogene|December 10, 2003
Microtubule-targeted anticancer agents and apoptosisKapil N Bhalla
Blood|May 7, 2016
NEDD8 and HDACs: promising cotargets in AMLKapil N Bhalla, Warren Fiskus
Cancer Biology & Therapy|August 17, 2005
Importance of rational pre-clinical development: gemcitabine comes of ageRamona F Swaby, Kapil N Bhalla
Blood|September 26, 2009
Missteps in "tango" for epigenome targetingKeith D Robertson, Kapil N Bhalla
Cancer Journal (Sudbury, Mass.)|September 20, 2017
Targeting Histone Acetylation: Readers and Writers in Leukemia and CancerChristopher B Benton, Warren Fiskus, Kapil N Bhalla
Oncotarget|December 8, 2017
Targeting cistrome and dysregulated transcriptome of post-MPN sAMLSrdan Verstovsek, Warren Fiskus, Taghi Manshouri, et al.
Hematology/Oncology Clinics of North America|September 27, 2012
Role of additional novel therapies in myeloproliferative neoplasmsWarren Fiskus, Siddhartha Ganguly, Suman Kambhampati, et al.
Molecular Pharmacology|January 27, 2006
Potent inhibition of platelet-derived growth factor-induced responses in vascular smooth muscle cells by BMS-354825 (dasatinib)Zhengming Chen, Francis Y Lee, Kapil N Bhalla, et al.
Expert Opinion on Investigational Drugs|August 13, 2009
Investigational drugs targeting FLT3 for leukemiaCelalettin Ustun, David L DeRemer, Anand P Jillella, et al.
Pageof 11